FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310811709> ?p ?o ?g. }

• W4310811709 endingPage "1254" @default.
• W4310811709 startingPage "1254" @default.
• W4310811709 abstract "Extra-pulmonary neuroendocrine carcinomas (EP-NECs) are rare, accounting for ~1/100,000 of NECs, aggressive neoplasms and poor prognosis. Sometimes, a non-neuroendocrine component is also accompanying these EP-NECs. Curative surgery is suggested for early stage patients while system chemotherapy and locoregional radiotherapy are considered for advanced inoperable disease. Nonetheless, there was lack of standard second-line treatment strategy. Herein, we report a case of NEC involving a large cell neuroendocrine carcinoma (LCNEC) and adenocarcinoma of the gallbladder treated with a surufatinib-containing regimen in the second-line treatment setting and establish the efficacy of this regimen in the treatment of EP-NECs.A 58-year-old male presented with symptoms such as distension in the upper right abdomen and a palpable mass. The abdominal magnetic resonance imaging (MRI) scan showed a giant soft tissue mass in the left lobe of the liver, and liver biopsy suggested LCNEC with a non-neuroendocrine (NNE) component. Based on the available literature, a first-line therapy of oxaliplatin + gemcitabine + camrelizumab + apatinib was started initially; however, there was rapid tumor progression. Thus, a second line of treatment was started, where apatinib was replaced with surufatinib, which was given along with oxaliplatin and camrelizumab and continued for seven complete cycles. The patient was re-examined with MRI, which showed a significant decrease in tumor size. And a partial response was achieved. Main adverse events included hand and foot numbness, hypertension, proteinuria, hematuria, and hyperthyroidism. The patient underwent surgery after the second line of treatment and the post-operative pathology report revealed the presence of LCNEC and adenocarcinoma of the gallbladder. Two months later, re-examination result showed no tumor recurrence.As yet, the criteria strategy for unresectable EP-NECs to improve survival outcomes is scarce. EP-NECs are badly in need of effective second-line therapy to carry out survival benefits after resistance to first-line regimen. The case report demonstrated that a surufatinib-containing regimen including oxaliplatin and camrelizumab could be an effective treatment strategy for the second-line treatment of EP-NECs. Furthermore, this strategy is well tolerated and treatment-related toxicity are manageable. More clinical trials are warranted to further confirm the efficacy." @default.
• W4310811709 created "2022-12-18" @default.
• W4310811709 creator A5005092860 @default.
• W4310811709 creator A5033237840 @default.
• W4310811709 creator A5036457690 @default.
• W4310811709 creator A5036779163 @default.
• W4310811709 creator A5041058568 @default.
• W4310811709 creator A5049815220 @default.
• W4310811709 creator A5066259971 @default.
• W4310811709 date "2022-11-01" @default.
• W4310811709 modified "2023-10-01" @default.
• W4310811709 title "The efficacy of oxaliplatin, surufatinib, and camrelizumab on neuroendocrine carcinoma: a case report and literature review" @default.
• W4310811709 cites W1871271676 @default.
• W4310811709 cites W1995500369 @default.
• W4310811709 cites W2042796936 @default.
• W4310811709 cites W2119631749 @default.
• W4310811709 cites W2149693604 @default.
• W4310811709 cites W2227093581 @default.
• W4310811709 cites W2336877383 @default.
• W4310811709 cites W2360931050 @default.
• W4310811709 cites W2728245744 @default.
• W4310811709 cites W2775732618 @default.
• W4310811709 cites W2950933915 @default.
• W4310811709 cites W2969542839 @default.
• W4310811709 cites W3011231712 @default.
• W4310811709 cites W3014625417 @default.
• W4310811709 cites W3030771474 @default.
• W4310811709 cites W3087054706 @default.
• W4310811709 cites W3087238097 @default.
• W4310811709 cites W3087682866 @default.
• W4310811709 cites W3093964219 @default.
• W4310811709 cites W3132032601 @default.
• W4310811709 cites W3138912036 @default.
• W4310811709 cites W3144492724 @default.
• W4310811709 cites W3170049297 @default.
• W4310811709 cites W3184493479 @default.
• W4310811709 cites W3193045657 @default.
• W4310811709 cites W4220719129 @default.
• W4310811709 cites W4220983609 @default.
• W4310811709 cites W4225539623 @default.
• W4310811709 cites W4226026458 @default.
• W4310811709 cites W4292369348 @default.
• W4310811709 doi "https://doi.org/10.21037/atm-22-4789" @default.
• W4310811709 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36544653" @default.
• W4310811709 hasPublicationYear "2022" @default.
• W4310811709 type Work @default.
• W4310811709 citedByCount "1" @default.
• W4310811709 countsByYear W43108117092023 @default.
• W4310811709 crossrefType "journal-article" @default.
• W4310811709 hasAuthorship W4310811709A5005092860 @default.
• W4310811709 hasAuthorship W4310811709A5033237840 @default.
• W4310811709 hasAuthorship W4310811709A5036457690 @default.
• W4310811709 hasAuthorship W4310811709A5036779163 @default.
• W4310811709 hasAuthorship W4310811709A5041058568 @default.
• W4310811709 hasAuthorship W4310811709A5049815220 @default.
• W4310811709 hasAuthorship W4310811709A5066259971 @default.
• W4310811709 hasBestOaLocation W43108117091 @default.
• W4310811709 hasConcept C121608353 @default.
• W4310811709 hasConcept C126322002 @default.
• W4310811709 hasConcept C126838900 @default.
• W4310811709 hasConcept C141071460 @default.
• W4310811709 hasConcept C143409427 @default.
• W4310811709 hasConcept C143998085 @default.
• W4310811709 hasConcept C2776694085 @default.
• W4310811709 hasConcept C2780258809 @default.
• W4310811709 hasConcept C2780962732 @default.
• W4310811709 hasConcept C2781413609 @default.
• W4310811709 hasConcept C509974204 @default.
• W4310811709 hasConcept C526805850 @default.
• W4310811709 hasConcept C71924100 @default.
• W4310811709 hasConceptScore W4310811709C121608353 @default.
• W4310811709 hasConceptScore W4310811709C126322002 @default.
• W4310811709 hasConceptScore W4310811709C126838900 @default.
• W4310811709 hasConceptScore W4310811709C141071460 @default.
• W4310811709 hasConceptScore W4310811709C143409427 @default.
• W4310811709 hasConceptScore W4310811709C143998085 @default.
• W4310811709 hasConceptScore W4310811709C2776694085 @default.
• W4310811709 hasConceptScore W4310811709C2780258809 @default.
• W4310811709 hasConceptScore W4310811709C2780962732 @default.
• W4310811709 hasConceptScore W4310811709C2781413609 @default.
• W4310811709 hasConceptScore W4310811709C509974204 @default.
• W4310811709 hasConceptScore W4310811709C526805850 @default.
• W4310811709 hasConceptScore W4310811709C71924100 @default.
• W4310811709 hasIssue "22" @default.
• W4310811709 hasLocation W43108117091 @default.
• W4310811709 hasLocation W43108117092 @default.
• W4310811709 hasLocation W43108117093 @default.
• W4310811709 hasOpenAccess W4310811709 @default.
• W4310811709 hasPrimaryLocation W43108117091 @default.
• W4310811709 hasRelatedWork W1996550290 @default.
• W4310811709 hasRelatedWork W2005187016 @default.
• W4310811709 hasRelatedWork W2028640470 @default.
• W4310811709 hasRelatedWork W2116856076 @default.
• W4310811709 hasRelatedWork W2120848645 @default.
• W4310811709 hasRelatedWork W2347878167 @default.
• W4310811709 hasRelatedWork W2364146720 @default.
• W4310811709 hasRelatedWork W2383559318 @default.
• W4310811709 hasRelatedWork W2590585323 @default.

• next